Based on these clues, SNS-targeted anti-obesity agents that increase the resting metabolic rate or thermogenesis in adipose tissues by enhancing β3-AR signaling have been the subjects of ongoing investigations over the past 20 years. Here, ADRB3 is linked to obesity disorder.